Telesis Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Telesis Bio şirketinin toplam hissedar öz sermayesi $9.9M ve toplam borcu $5.3M olup, bu da borç-öz sermaye oranını 53.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $52.7M ve $42.8M dir.

Anahtar bilgiler

53.1%

Borç/özkaynak oranı

US$5.28m

Borç

Faiz karşılama oranı	n/a
Nakit	US$10.21m
Eşitlik	US$9.95m
Toplam yükümlülükler	US$42.78m
Toplam varlıklar	US$52.73m

Son finansal sağlık güncellemeleri

Recent updates

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Apr 17

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Aug 09

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 25

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

Jan 06

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Sep 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TBIO 'nin kısa vadeli varlıkları ( $15.2M ) kısa vadeli yükümlülüklerini ( $8.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: TBIO 'un kısa vadeli varlıkları ( $15.2M ) uzun vadeli yükümlülüklerini ( $34.8M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TBIO şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: TBIO şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TBIO son raporlanan serbest nakit akışına göre 5 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: TBIO serbest nakit akışı tahminlerine göre 4 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Telesis Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Telesis Bio Receives Non-Compliance Letter from Nasdaq

Telesis Bio Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Telesis Bio Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Recent updates

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Yuan (Terry) Yang entered into an agreement to acquire Eton Bioscience, Inc. from Telesis Bio, Inc. (NasdaqGS:TBIO) for $1.5 million

Telesis Bio Receives Non-Compliance Letter from Nasdaq

Telesis Bio Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Announces Chief Executive Officer Changes

Telesis Bio, Inc., Annual General Meeting, May 01, 2024

Telesis Bio, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Telesis Bio Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Provides Earnings Guidance for 2023

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Telesis Bio, Inc. Announces Board Changes

Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations

Telesis Bio, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Telesis Bio, Inc. Appoints Paul Meister as Director

Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor

Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm

Telesis Bio, Inc., Annual General Meeting, Jul 06, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Forecast to breakeven in 2025

Consensus estimates of losses per share improve by 17%

Forecast to breakeven in 2025

Telesis Bio Releases BioXp Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Telesis Bio Provides Revenue Guidance for the Fourth Quarter of 2022

President recently bought US$192k worth of stock

Price target decreased to US$6.50

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Telesis Bio, Inc. Revises Revenue Guidance for the Full Year 2022

Telesis Bio, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Codex DNA, Inc. Announces Resignation of Brent Hunter as Vice President, Finance

Codex DNA, Inc. Expands Application of Proprietary Error Correction Technology

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

Codex Dna Debuts Next-Generation Automated Synthetic Biology Workstation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Codex DNA, Inc. Raises Revenue Guidance for the Full Year of 2022

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Codex DNA, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Codex DNA, Inc. Appoints Annette Tumolo to Serve as A Class III Director

Codex DNA, Inc.(NasdaqGS:DNAY) dropped from Russell 2500 Value Index

Codex DNA, Inc. Appoints Eric Esser to Serve as the Chief Operating Officer

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Codex DNA, Inc. to Report Q1, 2022 Results on May 10, 2022

Codex DNA, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Codex Dna, Inc. Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development At World Vaccine Congress Washington 2022

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Codex DNA, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Codex DNA, Inc. Showcases Potential of SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

High number of new and inexperienced directors

Codex DNA, Inc. Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant

Codex DNA, Inc. Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System

Third quarter 2021 earnings released: US$0.34 loss per share

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Senior Vice President of Commercial Operations Timothy Cloutier has left the company

Codex DNA, Inc. has completed an IPO in the amount of $106.66664 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin